Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

JAMA

Angiotensin-receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors were not associated with COVID-19 severity or mortality in a JAMA Cardiology study. Researchers looked at 360 COVID-19 patients with hypertension who were hospitalized in Wuhan from Jan. 15 to Mar. 15. Use of ARBs or ACE inhibitors did not differ significantly between those with severe and those with nonsevere disease (33% vs. 31%) or between nonsurvivors and survivors (27% vs. 33%). The authors conclude: “These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic.”

https://jamanetwork.com/journals/jamacardiology/fullarticle/2765049